As of 2025-07-08, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -12.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 485.86 mil USD. TBPH's TTM EBITDA according to its financial statements is -39.69 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.3x - 7.3x | 5.6x |
| Forward P/E multiples | 5.0x - 6.9x | 5.8x |
| Fair Price | (2.60) - (3.85) | (2.93) |
| Upside | -123.0% - -134.1% | -125.9% |
| Date | EV/EBITDA |
| 2025-07-03 | -12.04 |
| 2025-07-02 | -11.91 |
| 2025-07-01 | -11.74 |
| 2025-06-30 | -11.89 |
| 2025-06-27 | -12.13 |
| 2025-06-26 | -11.51 |
| 2025-06-25 | -11.32 |
| 2025-06-24 | -11.43 |
| 2025-06-23 | -11.31 |
| 2025-06-20 | -11.38 |
| 2025-06-18 | -11.37 |
| 2025-06-17 | -11.35 |
| 2025-06-16 | -11.54 |
| 2025-06-13 | -11.46 |
| 2025-06-12 | -11.36 |
| 2025-06-11 | -11.36 |
| 2025-06-10 | -11.51 |
| 2025-06-09 | -11.79 |
| 2025-06-06 | -12.16 |
| 2025-06-05 | -11.56 |
| 2025-06-04 | -11.86 |
| 2025-06-03 | -12.00 |
| 2025-06-02 | -12.04 |
| 2025-05-30 | -9.53 |
| 2025-05-29 | -9.71 |
| 2025-05-28 | -9.52 |
| 2025-05-27 | -9.68 |
| 2025-05-23 | -9.71 |
| 2025-05-22 | -9.95 |
| 2025-05-21 | -9.85 |
| 2025-05-20 | -9.90 |
| 2025-05-19 | -9.82 |
| 2025-05-16 | -9.58 |
| 2025-05-15 | -9.51 |
| 2025-05-14 | -8.59 |
| 2025-05-13 | -9.22 |
| 2025-05-12 | -9.08 |
| 2025-05-09 | -9.31 |
| 2025-05-08 | -10.46 |
| 2025-05-07 | -10.58 |
| 2025-05-06 | -10.70 |
| 2025-05-05 | -10.96 |
| 2025-05-02 | -11.06 |
| 2025-05-01 | -11.08 |
| 2025-04-30 | -10.30 |
| 2025-04-29 | -9.96 |
| 2025-04-28 | -10.28 |
| 2025-04-25 | -10.28 |
| 2025-04-24 | -10.01 |
| 2025-04-23 | -9.90 |